Role of Traditional Cigarettes, Electronic and IQOS Cigarettes on Oxidative Stress.

NCT03301129 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-03-29

No results posted yet for this study

Summary

Electronic cigarettes (E-cigarettes) and new heat-not-burn tobacco products such as IQOS®, an electronic device that heats a cigarette-like stick without combustion, are a modern and technological surrogate of traditional tobacco cigarettes (T-cigarettes), that are entering in the commercial market. While the negative effects of the traditional cigarette are well known, little data are reported in scientific literature on the risks on the health by these new smoking devices. Endothelial dysfunction evaluated by flow-mediated dilatation (FMD), oxidative stress and platelet activation have been recognized as a hallmark of preclinical systemic atherosclerosis and as a useful marker to stratify the risk of cardiovascular disease in patients at risk or with established clinically significant atherosclerosis. Since no data are reported about the effects of these new smoking device on oxidative stress, platelet activation and FMD, the investigators designed a human study assessing if these new smoking devices have effects on healthy smokers.

Conditions

  • Oxidative Stress Induction
  • Endothelial Dysfunction
  • Platelet Activation

Interventions

BEHAVIORAL

Smoke

See arm/group descriptions.

Sponsors & Collaborators

  • Coluzzi Flaminia

    collaborator UNKNOWN
  • Peruzzi Mariangela

    collaborator UNKNOWN
  • Nocella Cristina

    collaborator UNKNOWN
  • Loffredo Lorenzo

    collaborator UNKNOWN
  • Marullo Antonino G.M.

    collaborator UNKNOWN
  • Valenti Valentina

    collaborator UNKNOWN
  • Chimenti Isotta

    collaborator UNKNOWN
  • De Falco Elena

    collaborator UNKNOWN
  • Sciarretta Sebastiano

    collaborator UNKNOWN
  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Giacomo Frati, MD · Sapienza University of Rome, Policlinico Umberto I

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-15
Primary Completion
2018-01-30
Completion
2018-02-25

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03301129 on ClinicalTrials.gov